Skip to main content

Advertisement

Table 2 TCGA actionable landscape in different publications

From: From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

  Standard therapy Clinical trials Preclinical Total Number of TCGA samples Databases used by the study
Label Off-label Label Off-label Label Off-label    
MTB 9.9 (A1) 22.7 (B1) 64.1 (A2) 89 (B2) 90.6 (A3) 94.1 (B3) 94 3184 GDKD, CIViC, TARGET
Dienstmann et al. 2015 [20] 11 (5) 39 (4) 75 (3) 93 (1-2) 93 4392 GDKD
Rubio-Perez et al. 2015 [19] 5.9 40.2 73.3 73.3 4068 Rubio-Perez et al. 2015
Chakravarty et al. 2017 [18] 7.5 (1–2A) 16 (2B) 26 (3A) 41 (3B) 41 5983 OncoKB
  1. The table shows the cumulative percentages of patients with actionable variants identified at different levels. The name of the levels used in each publication are specified in parentheses. The studies being compared are: MTB (this publication), Chakravarty et al. 2017 [18], Dienstmann et al. 2015 [20], and Rubio-Perez et al. 2015 [19]